NASDAQ:BCTX
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. reported net income of −$26.3M in fiscal 2025. The diluted share count rose 285.7%.Summary generated from BriaCell Therapeutics Corp.'s SEC filings. Latest annual report filed Oct 16, 2025.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−359.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+285.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −7 | −15 | −23 | −33 | −27 |
| Net income | −14 | −27 | −20 | −5 | −26 |
| Free cash flow | n/a | n/a | n/a | −25 | n/a |
Recent filings
- 8-KRegulation FD disclosure
Jun 26, 2026 - 10-QQuarterly report for the period ended Apr 30, 2026
Jun 9, 2026 - 8-KEntry into a material agreement
Jun 3, 2026 - 8-KRegulation FD disclosure
Mar 31, 2026 - 10-QQuarterly report for the period ended Jan 31, 2026
Mar 10, 2026 - 8-KResults of a shareholder vote
Mar 9, 2026 - 8-KOther events
Feb 20, 2026 - DEF 14AProxy statement
Feb 12, 2026